HNGE delivered an emphatic post-IPO statement this week. Q1 results smashed expectations, and the resulting flood of analyst upgrades tells a clear story: the Street is chasing the stock higher.
The earnings print itself was the week's defining event. Q1 adjusted EPS came in at $0.45, well above the $0.38 consensus. Revenue of $182.3 million beat estimates of $172.2 million by a meaningful margin. More striking was the full-year guidance revision — management lifted FY2026 sales guidance to $798–804 million from $732–742 million, a raise of roughly $60 million at the midpoint that dwarfed the prior $735.9 million consensus. Q2 guidance of $194–196 million also ran materially ahead of the $179 million the Street had modelled. The stock climbed 11.2% on the week to close at $49.75, and rose another 1.8% on the day the analyst notes hit.
The analyst response was unanimous and immediate. Seven firms raised their price targets on May 6 alone, all while maintaining positive ratings. Wells Fargo and Citizens moved the highest, both lifting targets to $80. RBC Capital raised to $65, Barclays to $62, Stifel to $67, Needham to $63, and Canaccord Genuity to $63. Not a single firm downgraded. The consensus mean target has moved to $69.53, implying roughly 40% upside from current levels — though the gap between current price at $49.75 and targets warrants watching as targets continue to reprice toward the stock. The direction of travel is unambiguous: this was a beat-and-raise quarter that forced a reassessment across the board.
The bull case centres on Hinge Health's AI-powered motion tracking platform and demonstrated ability to reduce employer healthcare costs. EPS momentum over the trailing 90 days ranks in the 92nd percentile across the universe — near the top of the field — and the company has an EPS surprise rank of 68, reflecting a pattern of beating estimates. Bears point to rich valuation multiples, with the P/E near 24x and price-to-book at 9.7x, up roughly 1.8x in the past month as the stock re-rated sharply. The competitive landscape in digital musculoskeletal care is intensifying, and the company's newer HingeSelect product line raises some cannibalization questions among sceptical analysts. The EV/EBITDA multiple at 20.8x has been broadly stable over the month, suggesting the market is pricing in growth rather than re-rating the base.
Short interest entering the week already told a quieter story. SI ran at roughly 10% of free float — material but not extreme — and has been falling steadily since mid-April, down 5.2% over the week and 4.4% over the month. Borrow remains cheap at 0.43% annualised, barely changed week-on-week. With availability at 958% of short interest, the lending market is effectively wide open — there is no squeeze mechanism building here. The ORTEX short score has eased to 47.5 from above 49 two weeks ago, consistent with a gradual unwinding rather than an aggressive re-short. Options positioning is mildly bullish: the put/call ratio at 0.39 sits just below its 20-day average of 0.41, with a z-score near zero — no unusual hedging demand at this price level.
Insider selling has been consistent and worth flagging. Founder and Executive Chairman Gabriel Mecklenburg has sold shares twice in six weeks — 49,332 shares on April 1 at $38.45 and another 33,333 on April 21 at $45.05, together totalling around $3.4 million. CFO James Budge sold in both April and May. President Jim Pursley has also sold at each monthly interval. Net insider selling over 90 days amounts to approximately $35.3 million across 852,959 shares. These look like structured selling programmes rather than directional signals — the timing aligns with regular monthly cadences — but the volume is notable for a stock that has risen 28% in the past month. On the institutional side, Eleven Two Capital added 2.7 million shares in Q1, and Vanguard added 1.4 million, providing some counterweight to the founder and early-backer selling from Atomico and Coatue.
The next earnings event is scheduled for June 3, a full month ahead. Between now and then, the question for traders is whether the analyst target repricing — still underway as of this writing — draws fresh institutional buying, or whether the persistence of insider selling and a rich valuation keep gains in check.
See the live data behind this article on ORTEX.
Open HNGE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
